Clinical Pros of Sacituzumab and T-DXd

Opinion
Video

Panelists discuss how sacituzumab shows significant efficacy in triple-negative breast cancer, with improved progression-free and overall survival. It demonstrates particular benefit in pretreated patients and brain metastases cases. Trastuzumab deruxtecan (T-DXd) excels in HER2-positive breast cancer treatment, showing remarkable response rates and survival benefits, including in patients with brain metastases and those who progressed on prior therapies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content
No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH
November 15th 2017
Podcast

In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

Kristie L. Kahl
April 22nd 2024
Article

Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD
April 7th 2017
Podcast

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

Ariana Pelosci
March 22nd 2024
Article

The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

Russ Conroy
February 13th 2024
Article

The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.